Scopus BioPharma (SCPS) Competitors $0.0003 +0.00 (+50.00%) (As of 12/20/2024 02:14 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends SCPS vs. VAXX, NAVB, EVLO, GNCAQ, GNCA, ARDS, STAB, AMPE, CMRA, and CALAShould you be buying Scopus BioPharma stock or one of its competitors? The main competitors of Scopus BioPharma include Vaxxinity (VAXX), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry. Scopus BioPharma vs. Vaxxinity Navidea Biopharmaceuticals Evelo Biosciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals Comera Life Sciences Calithera Biosciences Vaxxinity (NASDAQ:VAXX) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Is VAXX or SCPS more profitable? Company Net Margins Return on Equity Return on Assets VaxxinityN/A N/A N/A Scopus BioPharma N/A N/A N/A Which has more risk & volatility, VAXX or SCPS? Vaxxinity has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.17, indicating that its share price is 117% less volatile than the S&P 500. Which has stronger valuation & earnings, VAXX or SCPS? Scopus BioPharma has lower revenue, but higher earnings than Vaxxinity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxxinity$70K0.54-$56.93M-$0.450.00Scopus BioPharmaN/AN/A-$11.61MN/AN/A Does the media prefer VAXX or SCPS? In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Vaxxinity Neutral Scopus BioPharma Neutral Do insiders and institutionals have more ownership in VAXX or SCPS? 82.9% of Vaxxinity shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community prefer VAXX or SCPS? Vaxxinity received 3 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote. CompanyUnderperformOutperformVaxxinityOutperform Votes538.46% Underperform Votes861.54% Scopus BioPharmaOutperform Votes2100.00% Underperform VotesNo Votes SummaryVaxxinity beats Scopus BioPharma on 5 of the 7 factors compared between the two stocks. Ad Porter & CompanyVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Get Scopus BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPS vs. The Competition Export to ExcelMetricScopus BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13,000.00$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.0517.20Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book0.005.094.784.78Net Income-$11.61M$151.83M$120.31M$225.60M7 Day PerformanceN/A-2.14%-1.92%-1.23%1 Month PerformanceN/A-4.56%13.65%0.46%1 Year PerformanceN/A8.87%28.34%15.24% Scopus BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPSScopus BioPharmaN/A$0.00+50.0%N/A-99.3%$13,000.00N/A0.009Gap UpVAXXVaxxinityN/A$0.00+100.0%N/A-100.0%$25,000.00$70,000.000.0090NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-99.8%$10,000.00$8,126.000.0010Analyst ForecastEVLOEvelo BiosciencesN/A$0.00+25.0%N/A-99.1%$9,000.00N/A0.00120GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.64M0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.9%$5,000.00$3.09M0.0030News CoverageSTABStatera BiopharmaN/A$0.00flatN/A-75.0%$5,000.00$1.49M0.0020AMPEAmpio PharmaceuticalsN/A$0.00+420.0%N/A-99.9%$3,000.00N/A0.0020Analyst ForecastCMRAComera Life SciencesN/A$0.00flatN/AN/A$3,000.00$630,000.000.002CALACalithera BiosciencesN/A$0.00-92.1%N/A-99.7%$1,000.00$9.75M0.0060Analyst ForecastGap Down Related Companies and Tools Related Companies Vaxxinity Competitors Navidea Biopharmaceuticals Competitors Evelo Biosciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Ampio Pharmaceuticals Competitors Comera Life Sciences Competitors Calithera Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SCPS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scopus BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scopus BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SCPS Stock Alerts